Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings

Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated the relationship between its relative dose intensity (RDI) and response in clinical settings. Methods: From March 2018 to May 2019, 93 patients were administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Ryu, Fukushima, Masanori, Haraguchi, Masafumi, Miuma, Satoshi, Miyaaki, Hisamitsu, Hidaka, Masaaki, Eguchi, Susumu, Matsuo, Satoshi, Tajima, Kazuaki, Matsuzaki, Toshihisa, Hashimoto, Satsuki, Ooba, Kazuo, Kugiyama, Yuki, Yatsuhashi, Hiroshi, Motoyoshi, Yasuhide, Shigeno, Masaya, Kinoshita, Noboru, Nakao, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895891/
https://www.ncbi.nlm.nih.gov/pubmed/31717674
http://dx.doi.org/10.3390/cancers11111769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895891/
https://www.ncbi.nlm.nih.gov/pubmed/31717674
http://dx.doi.org/10.3390/cancers11111769

Ejemplares similares